PROCEPT is scaling Aquablation and its HYDROS robotic platform for benign prostatic hyperplasia while building a longer-term prostate-cancer application around the same technology. Its 2026 plan emphasizes commercial expansion, procedure growth, international adoption and progress in the WATER IV prostate-cancer program.
The filing adds clinical credibility, not a new business initiative. The board increased its size from nine to ten directors and appointed Dr. Michael Mack, a veteran cardiac surgeon with extensive academic, surgical-trial and FDA-related leadership experience.
The fit is strategically relevant but indirect. Mack’s background in complex surgery, medical-device evaluation and clinical research could support PROCEPT as it seeks broader physician adoption and develops its prostate-cancer opportunity, but the 8-K does not announce a product decision, regulatory milestone, trial result or change in commercial plans. The company identifies its core business as urologic surgical robotics, with Aquablation for BPH and prostate cancer as a strategic adjacency.
There is no expectation-based upside to score. The appointment is independent, follows standard director compensation and indemnification terms, and includes no disclosed related-party arrangement. 〔0〕 That makes this a governance enhancement rather than a change to revenue, funding, guidance or execution.
Bottom line: This modestly strengthens PROCEPT’s clinical and regulatory bench as it expands beyond BPH, but it does not materially change the operating story today.وبه
Read the original 8-K on SEC EDGAR ↗